Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Non-Current Assets (2021 - 2025)

Aligos Therapeutics' Other Non-Current Assets history spans 5 years, with the latest figure at $715000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 14.04% year-over-year to $715000.0; the TTM value through Dec 2025 reached $715000.0, up 14.04%, while the annual FY2025 figure was $715000.0, 14.04% up from the prior year.
  • Other Non-Current Assets reached $715000.0 in Q4 2025 per ALGS's latest filing, roughly flat from $713000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.6 million in Q1 2022 to a low of $21000.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $490100.0, with a median of $626000.0 recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: plummeted 89.12% in 2022, then soared 814.29% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $866000.0 in 2021, then decreased by 26.79% to $634000.0 in 2022, then crashed by 88.96% to $70000.0 in 2023, then skyrocketed by 795.71% to $627000.0 in 2024, then grew by 14.04% to $715000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Other Non-Current Assets are $715000.0 (Q4 2025), $713000.0 (Q3 2025), and $640000.0 (Q2 2025).